Navigation Links
Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
Date:12/9/2008

SOUTH SAN FRANCISCO, Calif., Dec. 9 /PRNewswire/ -- Proteolix, Inc. today announced positive clinical data demonstrating that the company's lead product, carfilzomib, has single-agent activity and promotes durable responses in patients with relapsed and refractory multiple myeloma. Carfilzomib is the first in a new class of specific proteasome inhibitors being developed by Proteolix for the treatment of hematologic malignancies and solid tumors.

Sundar Jagannath, M.D., Chief of the Multiple Myeloma Program, Bone Marrow and Blood Stem Cell Transplantation at St. Vincent's Comprehensive Cancer Center in New York, and Ravi Vij, M.D., Associate Professor of Medicine, Division of Oncology, Section of Bone Marrow Transplantation at Washington University School of Medicine, presented data from two ongoing Phase 2 clinical trials of carfilzomib in relapsed and refractory multiple myeloma patients during the Novel Therapies for Myeloma and Related Disorders oral session at the 50th Annual Meeting of the American Society of Hematology (ASH). Both Phase 2 clinical trials are being conducted by Proteolix in collaboration with the Multiple Myeloma Research Consortium (MMRC).

Activity in Relapsed and Refractory Multiple Myeloma Patients

Dr. Jagannath presented data from an ongoing, open-label, multi-center study of single-agent carfilzomib in multiple myeloma patients. All patients in this trial were refractory to their last treatment. Of 39 evaluable patients, ten (26%) achieved partial or minor responses and an additional 16 (41%) achieved stable disease. Importantly, responses have also been durable with median treatment duration of 240 days, or approximately eight months.

"Patients enrolled in this Phase 2 trial have previously failed bortezomib, lenalidomide, thalidomide, and stem cell transplant. Carfilzomib as a single-agent is well tolerated and has demonstrated encouraging a
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Proteolixs Carfilzomib Receives Orphan Drug Designation for Treatment of Multiple Myeloma
3. Proteolix Raises $79 Million in Series C Financing
4. Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)..., CALGARY and BLENHEIM, Ontario, Nov. 24 /PRNewswi... today it is acquiring the assets of Hyland Seeds,...rio. The addition of Hyland Seeds will further exp...e company anticipates the introduction of SmartSt... Tolerant Trait Technology in corn in 2012. The tr...
(Date:11/24/2009)... , REYKJAVIK, Iceland, November 24...Nasdaq: DCGN ) today announced the approval of all... Court for the District of Delaware,(the "Bankrupt...ition for,relief under Chapter 11 of the United St..., The orders issued by the Bankruptcy Court...
(Date:11/24/2009)..., SEATTLE, Nov. 24 Blue Marble Ene... Odessa Public Development Authority (OPDA) were r...ommunity Economic Revitalization Board (CERB) in a...,s first specialty biochemical biorefinery in Linc...ificantly speed the development of our biorefinery...
(Date:11/24/2009)..., DUBLIN, November 24 /PRNewswire-FirstCall/ ...al specialty biopharmaceutical company, today,anno...Medicines Agency for,velaglucerase alfa, the compa... the treatment of Type 1 Gaucher disease. This is ...alfa that has been submitted, with previous,submis...
Breaking Biology Technology:Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 3deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 4
...Matrix Scientific Group, Inc. (OTC Bulletin Board:...h and development biotechnology company focused on...ercial cryogenic stem cell bank and processing fac...al Report about trends in adult stem cells publish...sWorld ( http://www.LifeSciencesWorld.com ) that p...
...d artificial sweeteners partner to produce world,s... promises to bring innovation to baking aisle , ,...Cleveland-based manufacturer of the patented probi...ive partnership with Heartland Sweeteners , an In...ellness products and calorie-free sweeteners, to p...
...tgenology Study Reveals Conclusive Findings in the...PORT NEWS, Va., March 3 Breast-Specific Gamma Ima...ve imaging technique for the diagnosis of invasive...r that begins in the milk-producing glands (lobule...ues -- according to a study published in the Febru...
Other Biology Technology:Bio-Matrix Scientific Group, Inc. Highlighted in LifeSciencesWorld.com Special Report; Stem Cell Market Projected to Exceed $8 Billion Worldwide by 2016 2Ganeden Biotech and Heartland Sweeteners to Produce Probiotic Sweetener 2Ganeden Biotech and Heartland Sweeteners to Produce Probiotic Sweetener 3Breast-Specific Gamma Imaging (BSGI) Offers Greater Sensitivity Over Mammography, Ultrasound and MRI 2Breast-Specific Gamma Imaging (BSGI) Offers Greater Sensitivity Over Mammography, Ultrasound and MRI 3
(Date:11/25/2009)...Soil is the linchpin of the environment, where atm...that, many students see soil as "just dirt" a pla...educators are challenged with the task of helping ...ortance of soil in the environment. , A collabo...eachers at University of Nebraska-Lincoln, Oregon ...
(Date:11/24/2009)...en prescribed by traditional healers in Brazil to ...ch pain to fever and flu. , Now for the first tim...ble to scientifically prove the pain relieving pro...azilian mint. , Testing this ancient South Americ...la Rocha was able to show that when prepared as a ...
(Date:11/24/2009)...abby arteries from collapsing have been true life-...longer needed -- once the arteries are strengthene...d no choice but to leave them in place. , Prof. ...nt of Biomedical Engineering has developed a new p...ere they,re needed, then dissolves. , "Our new c...
Breaking Biology News(10 mins):It's not just dirt! 2Got a pain? -- Have a cup of Brazilian mint 2A coating for life 2Mylans President of Europe Middle East and Africa Elected President of European Generic Medicines Association 6393 1Mylans President of Europe Middle East and Africa Elected President of European Generic Medicines Association 6393 2MS Need Not Preclude Pregnancy 61660 1MS Need Not Preclude Pregnancy 61660 2Uni H A in France Signs Purchasing Agreement for Masimo SET 28R 29 Pulse Oximetry Products 14907 1Uni H A in France Signs Purchasing Agreement for Masimo SET 28R 29 Pulse Oximetry Products 14907 2Uni H A in France Signs Purchasing Agreement for Masimo SET 28R 29 Pulse Oximetry Products 14907 3Uni H A in France Signs Purchasing Agreement for Masimo SET 28R 29 Pulse Oximetry Products 14907 4
...ells to interact with T cells (lymph cells that pl... that such interactions do occur and demonstrated ...sults may help explain the altered immune response...ay be useful in developing therapies for viral hep...his study appear in the November 2006 issue of Hep...
...m controls HIV during the earliest phases of infec...ns of key immune-system molecules called HLA Class...gments of viral protein those molecules display to...ells. In a report in the November issue of PLOS M...ch Center at Massachusetts General Hospital (PARC/...
...ic obstructive pulmonary disease (COPD) attempt to... contradicts the conventional wisdom on the capabi...r attempted regional elastic fiber repair in sever...tillo, Alexander Patterson and Richard Pierce of W...of the University of Pennsylvania, Philadelphia; a...
Other Biology News:Interaction between lymph and liver cells may affect immune response 2Interaction between lymph and liver cells may affect immune response 3Early-stage immune system control of HIV may depend on inherited factors 2Early-stage immune system control of HIV may depend on inherited factors 3Lungs try to repair damaged elastic fibers 2
Aedesta Animal Organ/Tissue Perfusion from Lifeblood Medical, Inc.
Rat Anti-Mouse JAM-2 Monoclonal Antibody, Unconjugated from AbD Serotec
Rabbit Anti-CSNK2A1 Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
...ementary RNA Spikes for the normalization and cont... printing and for protocol assessment and optimiza...ling, hybridization stringency and background. Nor... Oligo Spots, and complementary RNA Spikes for the...
Biology Products: